Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joseph F Merola

Showing results (321-330 of 394) with videos related to

Pageof 40
Sort By:
Lupus Science & Medicine|March 4, 2021
RNA tape sampling in cutaneous lupus erythematosus discriminates affected from unaffected and healthy volunteer skinJoseph F Merola, Wenting Wang, Carrie G Wager, et al.
Dermatology and Therapy|November 25, 2021
Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis RegistryJessica A Walsh, Kristina Callis Duffin, Abby S Van Voorhees, et al.
RMD Open|October 19, 2021
Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 studyIain B McInnes, Koji Kato, Marina Magrey, et al.
Dermatology and Therapy|May 30, 2025
Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal SymptomsJoseph F Merola, Philip J Mease, April W Armstrong, et al.
The Journal of Rheumatology|July 17, 2019
Relationship Between Fatigue and Inflammation, Disease Duration, and Chronic Pain in Psoriatic Arthritis: An Observational DANBIO Registry StudyMarie Skougaard, Tanja Schjødt Jørgensen, Signe Rifbjerg-Madsen, et al.
Rheumatology (Oxford, England)|July 1, 2026
Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: novel insights from FOREMOSTLaura C Coates, Dafna D Gladman, Joseph F Merola, et al.
The New England Journal of Medicine|March 31, 2021
Trial of Upadacitinib and Adalimumab for Psoriatic ArthritisIain B McInnes, Jaclyn K Anderson, Marina Magrey, et al.
The Journal of Rheumatology|June 3, 2014
The International Dermatology Outcome Measures initiative as applied to psoriatic disease outcomes: a report from the GRAPPA 2013 meetingAlice B Gottlieb, April W Armstrong, Robin Christensen, et al.
Annals of the Rheumatic Diseases|August 20, 2024
Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trialLaure Gossec, Laura C Coates, Dafna D Gladman, et al.
Dermatology Online Journal|August 17, 2023
A national survey comparing practice patterns and residency training satisfaction for categorical dermatology versus combined internal medicine and dermatology trained physiciansJoohee Han, Sanna D Ronkainen, Audrey Jacobsen, et al.
Pageof 40

Showing results (321-330 of 394) with videos related to

Sort By:
Pageof 40
Lupus Science & Medicine|March 4, 2021
RNA tape sampling in cutaneous lupus erythematosus discriminates affected from unaffected and healthy volunteer skinJoseph F Merola, Wenting Wang, Carrie G Wager, et al.
Dermatology and Therapy|November 25, 2021
Demographics, Disease Characteristics, and Patient-Reported Outcomes Among Patients with Psoriasis Who Initiated Guselkumab in CorEvitas' Psoriasis RegistryJessica A Walsh, Kristina Callis Duffin, Abby S Van Voorhees, et al.
RMD Open|October 19, 2021
Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 studyIain B McInnes, Koji Kato, Marina Magrey, et al.
Dermatology and Therapy|May 30, 2025
Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal SymptomsJoseph F Merola, Philip J Mease, April W Armstrong, et al.
The Journal of Rheumatology|July 17, 2019
Relationship Between Fatigue and Inflammation, Disease Duration, and Chronic Pain in Psoriatic Arthritis: An Observational DANBIO Registry StudyMarie Skougaard, Tanja Schjødt Jørgensen, Signe Rifbjerg-Madsen, et al.
Rheumatology (Oxford, England)|July 1, 2026
Progression from oligoarticular to polyarticular psoriatic arthritis and apremilast as a disease modifier: novel insights from FOREMOSTLaura C Coates, Dafna D Gladman, Joseph F Merola, et al.
The New England Journal of Medicine|March 31, 2021
Trial of Upadacitinib and Adalimumab for Psoriatic ArthritisIain B McInnes, Jaclyn K Anderson, Marina Magrey, et al.
The Journal of Rheumatology|June 3, 2014
The International Dermatology Outcome Measures initiative as applied to psoriatic disease outcomes: a report from the GRAPPA 2013 meetingAlice B Gottlieb, April W Armstrong, Robin Christensen, et al.
Annals of the Rheumatic Diseases|August 20, 2024
Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trialLaure Gossec, Laura C Coates, Dafna D Gladman, et al.
Dermatology Online Journal|August 17, 2023
A national survey comparing practice patterns and residency training satisfaction for categorical dermatology versus combined internal medicine and dermatology trained physiciansJoohee Han, Sanna D Ronkainen, Audrey Jacobsen, et al.
Pageof 40